Navigation Links
Santaris Pharma presents positive preclinical data on SPC2996 at,the American Association for Cancer Research

>The protein Bcl-2, first identified in B-cell lymphoma/leukaemia cells from which its name derives, is one of a family of intracellular proteins regulating cell survival and cell death. Some types of cells in the body, for example blood cells, are programmed to die after a few weeks of life, in the case of blood cells to be replaced in the circulation by fresh cells produced in the bone marrow. This process of programmed cell death is known as apoptosis. Bcl-2 is an apoptosis suppressor protein, i.e. it extends the lifespan of the cell in the presence of normal apoptosis stimuli. The levels of Bcl-2 within the cell are frequently over-expressed in malignant cancers, and this is particularly the case in human chronic lymphocytic leukaemia and lymphoma where it acts to prolong the life of malignant white blood cells. Drugs which lower the concentration of Bcl-2 or inhibit its function may therefore have therapeutic benefit by inducing cancer cell death and removal without resorting to chemotherapy.

About SPC2966

SPC2996 is the first of a portfolio of novel experimental drugs blocking harmful gene expression being designed and developed by Santaris Pharma. The drug belongs to a new class of drugs called RNA Antagonists, proprietary to Santaris Pharma, based on the novel three-dimensional analogue of RNA known as Locked Nucleic Acid (LNA). The drug binds with high potency and specificity to the messenger RNA for Bcl-2 and destroys it within the cell, resulting in a reduction in Bcl-2 protein concentration. SPC2996 is an investigational product which has not yet been approved by any regulatory agency as effective or safe for patient use but the novel agent is currently being evaluated in international Phase I/II studies in human CLL in centres in Denmark, France, UK and the USA.

AACR Abstract

An Abstract of the work described in this release can be found on the American Association for Cancer Research (AACR) 2007 Annual Meeting database at th
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:3/27/2015)... Report Details  New study shows ... What does the future hold for top companies ... new report shows you potential revenues to 2025, assessing ... 242-page report provides 185 tables, charts, and graphs. Discover ... future market prospects. Our new study lets you assess ...
(Date:3/27/2015)... , March 27, 2015   Hospira, ... leader in biosimilars and the world,s leading provider ... studies that support an evaluation of biosimilarity of ... Food and Drug Administration (FDA) conditionally approved name ... EPOGEN™ (epoetin alfa). These study data were presented ...
(Date:3/27/2015)... 27, 2015 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution ... radiotherapy and diagnostic imaging centers in ... a purchase agreement under which Concord Medical Services ... the Company, agreed to acquire the Fortis Surgical ...
Breaking Medicine Technology:Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 2Hospira Clinical Data Shows Proposed Biosimilar, Epoetin Hospira, Demonstrates Pharmacokinetic And Pharmacodynamic Equivalence Compared To Amgen's Epogen 3Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 2Concord Medical Announces Acquisition of Fortis Surgical Hospital in Singapore 3
... Del. , April 30 AstraZeneca and ... Administration (FDA) has approved VIMOVO™ (naproxen and ... and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, ... in patients at risk of developing NSAID-associated gastric ulcers.(1) ...
... Mich. , April 30 The Editorial Advisory and Securities ... Industries Limited (Nasdaq: TEVA ) as its July 2010 ... GILD ) as its July "Undervalued Stock" for investors, informational and educational ... "The committee chose ...
Cached Medicine Technology:FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 2FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 3FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 4FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 5FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 6FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 7FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 8FDA Approved VIMOVO(TM) for Arthritis Patients At Risk of Developing NSAID-Associated Gastric Ulcers 9BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 2BetterInvesting Magazine Releases July's Stock to Study and Undervalued Stock Choices for Investors' Informational and Educational Use 3
(Date:3/28/2015)... 2015 Aureus Medical Group (web: ... physical therapy jobs, has announced that it will ... Therapy Association Annual Conference to be held April ... in Columbus, OH. , The OPTA Annual ... with products and services. , Representatives from ...
(Date:3/28/2015)... 28, 2015 The "Petrick Sustainable ... sustainable health. After 18 years of research and experience ... UFC contenders, Dr. Jon Petrick is excited to be ... some of the immediate benefits of this radical new ... levels of strength of the immune system, faster healing ...
(Date:3/28/2015)... 28, 2015 ARDX will sponsor the 7th ... -3pm at the Chesapeake Conference Center in Chesapeake, Virginia. ... empowering event for women in the Hampton Roads region. ... of Women’s Lives. Women grow stronger through sharing their ... This year the WWC™ theme is T-talk where we ...
(Date:3/28/2015)... March 28, 2015 Servpro of ... this week released a report about the link between ... asthma sufferers, and according to recent medical research, may ... According to the Environmental Protection Agency, people with sensitivity ... Breathing in mold may trigger asthma attacks for asthma ...
(Date:3/27/2015)... March 27, 2015 The Monogamy ... dating experts Samantha Sanderson and Jason Rogers has just ... of media attention. The commotion surrounding the course's launch ... him to publish an in-depth review of the new ... the men in their lives suddenly start pulling away ...
Breaking Medicine News(10 mins):Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:Celebrity Chiropractor Jon Petrick to Release Sustainable Health System this Summer 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 2Health News:Water Damage Restoration Specialists Servpro of Paso Robles Release Report on Mold and Asthma 3Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2
... HealthDay Reporter , TUESDAY, Aug. 16 (HealthDay News) ... be given radioactive iodine unnecessarily, while others with more ... new study suggests. More than 44,000 people are ... according to the study. When caught early, it is ...
... By Alan Mozes HealthDay Reporter , ... patients afflicted with a particularly severe, crippling form of ... ineffective, a recently approved alternative appears to afford relief. ... Krystexxa) has no effect on most severe gout patients, ...
... current expenses and largely unable to meet essential future ones, ... new poll from The SCAN Foundation and the UCLA Center ... its second year, sought to better understand health and long-term ... crisis and the rising number of Californians older than 60, ...
... scholar Cynthia Wu has spent years studying Chang and ... "human marvels." "The Bunker twins," she says, "have served ... paradox that while ,individualism, is what makes Americans stand ... assistant professor of American studies at the University at ...
... There was a dramatic increase in the number of children,s flu-related ... federal agency says. Over that time, flu rose from 65th ... and younger go to the hospital, according to a report from ... also found that skin infections rose from 13th to 7th in ...
... Medical Sciences of the National Institutes of Health recently ... cell biology in Wayne State University,s College of Liberal ... alteration of chromatin regulates cellular division and growth. The ... treatments currently undergoing clinical trials. Chromatin is a ...
Cached Medicine News:Health News:Some Thyroid Cancer Patients May Get Radioactive Iodine Unnecessarily 2Health News:Some Thyroid Cancer Patients May Get Radioactive Iodine Unnecessarily 3Health News:Some Thyroid Cancer Patients May Get Radioactive Iodine Unnecessarily 4Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 2Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 3Health News:New Drug May Relieve Severe, Tough-to-Treat Gout 4Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 2Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 3Health News:Poll finds two-thirds of California voters unprepared for costs of growing older 4Health News:Research on famous Siamese twins demonstrates how the paradox of American identity played out in the bodies of Chang and Eng 2Health News:Research on famous Siamese twins demonstrates how the paradox of American identity played out in the bodies of Chang and Eng 3Health News:NIH awards WSU researcher $1.39M to study chromatin's role in cell division 2
... a stand-alone real-time monitoring, recording and ... defined set up, continuous monitoring and ... humidity. It offers non-restrictive sensor placements ... banks, laboratories, refrigerators, freezers, incubators and ...
... As many as three tests confirmed ... two tests according to FDA (Time Kill ... Care Antiseptic Drug Products) and one European ... Rub meets the relevant international efficacy specifications. ...
HIBICLENS' non-drying, low skin irritation potential promotes compliance with the frequent hand washing associated with today's clinical protocols....
... Care® Brand soaps, emulsions, washes and ... in healthy skin care, helping to ... healthy and soft even with heavy, ... contain petroleum-based substances that can cause ...
Medicine Products: